Preparation and characterization of triclosan nanoparticles for periodontal treatment

被引:112
作者
Piñón-Segundo, E [1 ]
Ganem-Quintanar, A [1 ]
Alonso-Pérez, V [1 ]
Quintanar-Guerrero, D [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Dept Posgrad Farm, Fac Estudios Super Cuautitlan, Mexico City 54704, DF, Mexico
关键词
nanoparticles; emulsification-diffusion; triclosan; periodontal diseases; gingivitis; periodontitis;
D O I
10.1016/j.ijpharm.2004.11.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this work was to produce and characterize triclosan-loaded nanoparticles (NPs) by the emulsification-diffusion process, in an attempt to obtain a novel delivery system adequate for the treatment of periodontal disease. The NPs were prepared Using poly(D,L-lactide-co-glycolide) (PLGA), poly(D,L-lactide) (PLA) and cellulose acetate phthalate (CAP). Poly(vinyl alcohol) (PVAL) was used as stabilizer. Batches were prepared with different amounts of triclosan (TCS) in order to evaluate the influence of drug on NP properties. Solid NPs of less than 500 nm in diameter were obtained. Entrapment efficiencies were higher than 63.8%. The characterization by scanning electron microscopy and light scattering indicated that high concentrations of TCS seemingly caused the increase of NP mean size. A decrease in the PLGA glass transition temperature was observed by differential scanning calorimetry. This could indicate that TCS in PLGA-NPs behaves as a non-conventional plasticizer. Subsequently, in vitro release studies were carried out under sink conditions using a device designed in our laboratory to allow a direct contact between the particles and the dissolution medium. A fast release of TCS from NPs was detected. A preliminary in vivo study, in dogs with induced periodontal defects suggested that TCS-loaded NPs penetrate through the junctional epithelium. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:217 / 232
页数:16
相关论文
共 47 条
[1]  
ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P13
[2]  
BAKER RW, 1988, P 15 INT S CONTR REL, P140
[3]  
BAKER RW, 1988, P 15 INT S CONTR REL, pA238
[4]  
BRILL NIELS, 1959, ACTA ODONTOL SCAND, V17, P11, DOI 10.3109/00016355909011229
[5]  
BRILL NIELS, 1958, ACTA ODONTOL SCAND, V16, P233, DOI 10.3109/00016355809064110
[6]   Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers [J].
Calvo, P ;
VilaJato, JL ;
Alonso, MJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (05) :530-536
[7]  
Carrillo J, 2000, Rev ADM, V57, P205
[8]   Project, design, and use of a pilot plant for nanocapsule production [J].
Colombo, AP ;
Briancon, S ;
Lieto, J ;
Fessi, H .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2001, 27 (10) :1063-1072
[9]  
DOELKER E, 1985, FORMES PHARM NOUVELL, P34
[10]  
Drisko C H, 1996, Ann Periodontol, V1, P491, DOI 10.1902/annals.1996.1.1.491